3-((2'-carboxybiphenyl-4-yl)methyl)-2-cyclopropyl-7-methyl-3h-imidazo(4,5-b)pyridine has been researched along with Alloxan Diabetes in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gomi, T; Hirawa, N; Ikeda, T; Kawabata, Y; Numabe, A; Omata, M; Uehara, Y | 1 |
1 other study(ies) available for 3-((2'-carboxybiphenyl-4-yl)methyl)-2-cyclopropyl-7-methyl-3h-imidazo(4,5-b)pyridine and Alloxan Diabetes
| Article | Year |
|---|---|
Angiotensin II subtype-1 receptor antagonists improve hemodynamic and renal changes without affecting glucose metabolisms in genetic rat model of non-insulin-dependent diabetes mellitus.
Topics: Acetylglucosaminidase; Angiotensin Receptor Antagonists; Animals; Blood Glucose; Blood Pressure; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Imidazoles; Kidney Glomerulus; Organ Size; Pyridines; Rats; Rats, Long-Evans; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Treatment Outcome | 1999 |